GlassScriptPhysician profile
Elnaz Balashi
NPI 1275153025
$5,710.57
in general payments reported to CMS, 2019-2025
29 companies · $1,730 in 2025
The $1,730 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.68 · 2022: $408 · 2023: $445 · 2024: $3,107 · 2025: $1,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.17 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,126.11 | 2022-2025 | |
| Amgen INC. | $619.46 | 2021-2025 | Krystexxa, Tavneos, Otezla |
| Abbvie INC. | $586.69 | 2022-2025 | |
| Ucb, INC. | $434.22 | 2023-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $431.06 | 2024-2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $427.19 | 2024-2025 | Strensiq |
| Janssen Biotech, INC. | $312.27 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $214.99 | 2022-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $210.56 | 2023-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.41 | 2024-2025 | Ofev |
| Novartis Pharmaceuticals Corporation | $169.39 | 2025 | |
| Genentech USA, INC. | $161.60 | 2024-2025 | Gazyva, Actemra |
| Sanofi-Aventis U.S. LLC | $144.99 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $120.08 | 2024-2025 | Purified Cortrophin Gel, Sovuna |
| Aurinia Pharma U.S., INC. | $99.24 | 2022-2024 | Lupkynis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $95.58 | 2025 | Korlym |
| Alvogen INC | $74.64 | 2024 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $53.83 | 2024 | Arcalyst |
| Sobi, INC | $41.27 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $39.61 | 2023 | Idacio |
| Radius Health, INC. | $32.12 | 2025 | Tymlos |
| Pfizer INC. | $28.15 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.45 | 2025 | |
| Ascendis Pharma Endocrinology INC | $16.99 | 2025 | Yorvipath |
| Medtronic, INC. | $16.07 | 2025 | Minimed 780g |
| Lilly USA, LLC | $15.12 | 2025 | Zepbound, Mounjaro |
| Octapharma USA, INC. | $14.62 | 2023 | Octagam Immune Globulin (Human) |
| Averitas Pharma INC. | $14.52 | 2025 | Qutenza |
| Organon LLC | $12.34 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elnaz Balashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.